Elligo Health Research, an Austin, Texas-based developer of a platform that aims to improve clinical trial access, raised $16m in Series B funding.
The round was led by Hatteras Venture Partners and Noro-Moseley Partners with participation from FS Healthcare LLC, Excelerate Health Ventures and all existing Series A investors including Shumway Capital.
The investment will enable the company to accelerate expansion of its network of physicians and refine its technology platform.
Led by John Potthoff, Ph.D., CEO, and Chad Moore, president, Elligo provides a platform that aims to bring clinical research to the clinic, accelerating the development of new pharmaceutical, biotechnology and medical device products and therapies. Elligo Goes Direct™ uses electronic health records and other health data to identify real-world patients and physicians for participation in clinical studies.